Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.

Rojavin, Mikhail A; Hubsch, Alphonse; Lawo, John-Philip

Rojavin, Mikhail A; Hubsch, Alphonse; Lawo, John-Philip.

Affiliation

Rojavin MA; Clinical Research and Development, CSL Behring LLC, King of Prussia, PA, USA. Mikhail.Rojavin@cslbehring.com.
Hubsch A; Medical Affairs, CSL Behring AG, Berne, Switzerland.
Lawo JP; Clinical Research and Development, CSL Behring GmbH, Marburg, Germany.

J Clin Immunol ; 36(3): 210-9, 2016 Apr.

Article in En | MEDLINE | ID: mdl-26910102

Subject(s)

Immunoglobulin G/blood; Immunoglobulins, Intravenous/therapeutic use; Immunologic Deficiency Syndromes/drug therapy; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Resistance; Female; Humans; Immunoglobulins, Intravenous/blood; Immunologic Deficiency Syndromes/immunology; Immunologic Deficiency Syndromes/physiopathology; Infusions, Subcutaneous; Male; Middle Aged; Quality of Life; Treatment Outcome

Key words

Immunoglobulin replacement therapy; end-dose effect; ivig; primary immunodeficiency; scig; wear-off; well-being

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulins, Intravenous / Immunologic Deficiency Syndromes Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: J Clin Immunol Year: 2016 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google